Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
Phone+44-20-74017646
Debt
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
Employees15,000
OptionableOptionable
Smith & Nephew (LON:SN) Frequently Asked Questions
What is Smith & Nephew's stock symbol?
Smith & Nephew trades on the London Stock Exchange (LON) under the ticker symbol "SN."
How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?
Smith & Nephew announced a dividend on Thursday, July 26th. Stockholders of record on Thursday, October 4th will be paid a dividend of GBX 0.14 per share on Wednesday, October 31st. This represents a dividend yield of 0.77%. The ex-dividend date of this dividend is Thursday, October 4th. The official announcement can be viewed at this link. View Smith & Nephew's Dividend History.
What price target have analysts set for SN?
9 brokers have issued twelve-month target prices for Smith & Nephew's shares. Their predictions range from GBX 1,290 to GBX 1,692. On average, they anticipate Smith & Nephew's stock price to reach GBX 1,457.67 in the next year. This suggests a possible upside of 0.8% from the stock's current price. View Analyst Price Targets for Smith & Nephew.
What is the consensus analysts' recommendation for Smith & Nephew?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Smith & Nephew.
Has Smith & Nephew been receiving favorable news coverage?
Media stories about SN stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Smith & Nephew earned a news impact score of 2.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term.
Who are some of Smith & Nephew's key competitors?
Some companies that are related to Smith & Nephew include Bioquell (BQE), Consort Medical (CSRT), Corindus Vascular Robotics (CVRS), Deltex Medical Group (DEMG), Ekf Diagnostics (EKF), Immunodiagnostic Systems (IDH), InspireMD (NSPR), LiDCO Group (LID), Lucid (LCDX), Medaphor Group (MED), Theralase Technologies (TLT), Verisante Technology (VRS) and Zecotek Photonics (ZMS).
Who are Smith & Nephew's key executives?
Smith & Nephew's management team includes the folowing people:
- Mr. Graham Timothy Baker, CFO & Exec. Director (Age 50)
- Mr. Namal Nawana, CEO & Exec. Director (Age 47)
- Mr. Mark Gladwell, Pres of Global Operations (Age 43)
- Ms. Catheryn O'Rourke, Chief Legal & Compliance Officer (Age 45)
- Mr. Joe Metzger, Sr. VP of Marketing Services & Communications
How do I buy shares of Smith & Nephew?
Shares of SN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Smith & Nephew's stock price today?
One share of SN stock can currently be purchased for approximately GBX 1,446.
What is Smith & Nephew's official website?
How can I contact Smith & Nephew?
Smith & Nephew's mailing address is 15 Adam Street, LONDON, WC2N 6LA, United Kingdom. The company can be reached via phone at +44-20-74017646.
MarketBeat Community Rating for Smith & Nephew (LON SN)
MarketBeat's community ratings are surveys of what our community members think about Smith & Nephew and other stocks. Vote "Outperform" if you believe SN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SN will underperform the S&P 500 over the long term. You may vote once every thirty days.
